Within the Hemojuvelin Antibody Market , DISC-0974 is the most advanced clinical candidate. DISC-0974 is a monoclonal antibody that binds to hemojuvelin and blocks BMP signaling, thereby suppressing hepcidin production and increasing iron availability. It is currently being investigated for the treatment of anemia in patients with myelofibrosis (NCT05320198) and chronic kidney disease (NCT05745883).
Anemia is a common and debilitating complication of myelofibrosis, a rare bone marrow disorder characterized by abnormal blood cell production and fibrosis. Current treatment options for anemia in myelofibrosis are limited, and many patients become dependent on red blood cell transfusions. Preclinical studies have shown that DISC-0974 can effectively reduce hepcidin levels and improve anemia in animal models of myelofibrosis. Early-phase clinical trials are ongoing to evaluate its safety and efficacy in patients.
Anemia of chronic kidney disease (CKD) is another major target for DISC-0974. As kidney function declines, hepcidin levels often become inappropriately elevated, leading to iron restriction and reduced red blood cell production. Current treatments for anemia of CKD include erythropoiesis-stimulating agents (ESAs) and iron supplementation, but these therapies are not always effective and can have side effects. DISC-0974 offers a novel approach by targeting the underlying cause of iron restriction. A Phase 1b, double-blind, placebo-controlled study of DISC-0974 in patients with nondialysis-dependent CKD and anemia is currently underway. Preliminary results presented at the National Kidney Foundation 2024 Spring Clinical Meetings showed promising activity.
In addition to DISC-0974, other hemojuvelin-targeting antibodies are in preclinical development. For example, Scholar Rock is conducting preclinical research on inhibitors of RGMc/HJV (hemojuvelin) for the treatment of iron-restricted anemia. The company is advancing its program towards investigational new drug (IND)-enabling studies.
The therapeutic potential of hemojuvelin antibodies extends beyond anemia. A study published in 2024 showed that an anti-hemojuvelin monoclonal antibody reversed anemia and exerted disease-modifying effects in a mouse model of inflammatory bowel disease (IBD). This finding suggests that hemojuvelin antibodies may have broader applications in inflammatory conditions where hepcidin dysregulation plays a role.
The successful development of hemojuvelin antibodies would represent a significant advance in the treatment of iron metabolism disorders. By directly targeting the hemojuvelin-hepcidin axis, these therapies offer the potential to restore iron homeostasis and improve patient outcomes. The clinical progress of DISC-0974 is closely watched by the pharmaceutical industry, and positive results could trigger a wave of investment in this emerging field.
